These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7569503)

  • 1. Defining, monitoring and combining safety information in clinical trials.
    Enas GG; Goldstein DJ
    Stat Med; 1995 May 15-30; 14(9-10):1099-111; discussion 1113-6. PubMed ID: 7569503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to drug safety: a pharmacovigilance tool kit.
    Wise L; Parkinson J; Raine J; Breckenridge A
    Nat Rev Drug Discov; 2009 Oct; 8(10):779-82. PubMed ID: 19763106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
    Crowe BJ; Xia HA; Berlin JA; Watson DJ; Shi H; Lin SL; Kuebler J; Schriver RC; Santanello NC; Rochester G; Porter JB; Oster M; Mehrotra DV; Li Z; King EC; Harpur ES; Hall DB
    Clin Trials; 2009 Oct; 6(5):430-40. PubMed ID: 19846894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs.
    Vray M; Hamelin B; Jaillon P;
    Therapie; 2005; 60(4):339-44, 345-9. PubMed ID: 16268434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary by a child psychiatrist in industry on the assessment of drug safety.
    Allen AJ
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):288-91. PubMed ID: 17630860
    [No Abstract]   [Full Text] [Related]  

  • 8. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical drug investigations. Definition of terms].
    Johne A; Gerloff T; Mai I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):397-400. PubMed ID: 15830249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches.
    Prada-Ramallal G; Takkouche B; Figueiras A
    Drug Saf; 2017 Jul; 40(7):547-558. PubMed ID: 28299611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing surveillance: curriculum for the clinical pharmacologist. Part I: Postmarketing surveillance within the continuum of the drug approval process.
    Johnson J; Tanner LA
    J Clin Pharmacol; 1993 Oct; 33(10):904-11. PubMed ID: 8227459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval times and the safety of new pharmaceuticals.
    Rudholm N
    Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Benefits and harms - two sides of the same medal?].
    Koch A
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(3):163-70. PubMed ID: 21530904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale for a post-marketing surveillance.
    Westerholm B
    Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can expedited FDA drug approval without expedited follow-up be trusted?
    Carpenter D
    JAMA Intern Med; 2014 Jan; 174(1):95-7. PubMed ID: 24165977
    [No Abstract]   [Full Text] [Related]  

  • 19. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.
    Izem R; Sanchez-Kam M; Ma H; Zink R; Zhao Y
    Ther Innov Regul Sci; 2018 Mar; 52(2):159-169. PubMed ID: 29714520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.